GlassScriptPhysician profile
Stephen A Vannucci
NPI 1255405783
$4,632.57
in general payments reported to CMS, 2019-2025
20 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.54 · 2020: $335 · 2021: $246 · 2022: $1,079 · 2023: $1,321 · 2024: $994 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.23 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,410.56 | 2020-2025 | Tremfya, Remicade, Simponi Aria |
| Abbvie INC. | $1,264.20 | 2019-2025 | Skyrizi, Rinvoq |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $555.30 | 2023-2025 | Siliq, Jublia, Duobrii |
| Regeneron Healthcare Solutions, INC. | $315.90 | 2020-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $261.27 | 2023-2025 | |
| Amgen INC. | $229.46 | 2020-2024 | Otezla |
| Genzyme Corporation | $119.06 | 2019-2024 | |
| Lilly USA, LLC | $80.53 | 2019-2025 | Taltz, Ebglyss |
| Organon LLC | $68.58 | 2025 | Vtama |
| Ucb, INC. | $62.11 | 2020-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $60.63 | 2020-2023 | |
| Incyte Corporation | $50.65 | 2023 | Opzelura |
| Leo Pharma INC. | $39.48 | 2022-2025 | Anzupgo |
| Celgene Corporation | $19.02 | 2019 | |
| Pfizer INC. | $18.37 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.69 | 2020 | |
| Glaxosmithkline, LLC. | $16.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.47 | 2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $15.57 | 2023 | Ilumya |
| Novo Nordisk INC | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Vannucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.